Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Martin Knapp

Showing results (411-420 of 451) with videos related to

Pageof 46
Sort By:
The Lancet. Psychiatry|January 23, 2026
The implications of the COVID-19 pandemic for clinical mental health careAlexandra M Schuster, Nisreen A Alwan, Felicity Callard, et al.
The Lancet. Psychiatry|January 23, 2026
Policy and public health implications for mental health after the COVID-19 pandemicEtheldreda Nakimuli-Mpungu, Celso Arango, Rakhi Dandona, et al.
Journal of Alzheimer'S Disease : JAD|January 10, 2022
The Use and Costs of Paid and Unpaid Care for People with Dementia: Longitudinal Findings from the IDEAL CohortCatherine Henderson, Martin Knapp, Anthony Martyr, et al.
Dementia (London, England)|May 29, 2023
Transforming dementia research into policy change: A case study of the multi-country STRiDE projectWendy Weidner, Rochelle Amour, Erica Breuer, et al.
Alzheimer'S & Dementia (New York, N. Y.)|November 14, 2019
Use and costs of services and unpaid care for people with mild-to-moderate dementia: Baseline results from the IDEAL cohort studyCatherine Henderson, Martin Knapp, Sharon M Nelis, et al.
International Journal of Geriatric Psychiatry|February 23, 2018
A roadmap to advance dementia research in prevention, diagnosis, intervention, and care by 2025James Pickett, Cathy Bird, Clive Ballard, et al.
Journal of Psychopharmacology (Oxford, England)|October 25, 2006
Clinical practice with anti-dementia drugs: a consensus statement from British Association for PsychopharmacologyAlistair Burns, John O'Brien, , et al.
The British Journal of Psychiatry : the Journal of Mental Science|December 22, 2012
Cost-effectiveness analyses for mirtazapine and sertraline in dementia: randomised controlled trialRenee Romeo, Martin Knapp, Jennifer Hellier, et al.
Journal of Affective Disorders|February 8, 2026
Effectiveness of an integrated prevention programme ("JoyAge") for depressive symptoms, anxiety, and loneliness in older adults in Hong Kong: A pragmatic quasi-experimental trialTianyin Liu, Dara Kiu Yi Leung, Daniel Wong, et al.
Lancet (London, England)|October 24, 2021
Study of mirtazapine for agitated behaviours in dementia (SYMBAD): a randomised, double-blind, placebo-controlled trialSube Banerjee, Juliet High, Susan Stirling, et al.
Pageof 46

Showing results (411-420 of 451) with videos related to

Sort By:
Pageof 46
The Lancet. Psychiatry|January 23, 2026
The implications of the COVID-19 pandemic for clinical mental health careAlexandra M Schuster, Nisreen A Alwan, Felicity Callard, et al.
The Lancet. Psychiatry|January 23, 2026
Policy and public health implications for mental health after the COVID-19 pandemicEtheldreda Nakimuli-Mpungu, Celso Arango, Rakhi Dandona, et al.
Journal of Alzheimer'S Disease : JAD|January 10, 2022
The Use and Costs of Paid and Unpaid Care for People with Dementia: Longitudinal Findings from the IDEAL CohortCatherine Henderson, Martin Knapp, Anthony Martyr, et al.
Dementia (London, England)|May 29, 2023
Transforming dementia research into policy change: A case study of the multi-country STRiDE projectWendy Weidner, Rochelle Amour, Erica Breuer, et al.
Alzheimer'S & Dementia (New York, N. Y.)|November 14, 2019
Use and costs of services and unpaid care for people with mild-to-moderate dementia: Baseline results from the IDEAL cohort studyCatherine Henderson, Martin Knapp, Sharon M Nelis, et al.
International Journal of Geriatric Psychiatry|February 23, 2018
A roadmap to advance dementia research in prevention, diagnosis, intervention, and care by 2025James Pickett, Cathy Bird, Clive Ballard, et al.
Journal of Psychopharmacology (Oxford, England)|October 25, 2006
Clinical practice with anti-dementia drugs: a consensus statement from British Association for PsychopharmacologyAlistair Burns, John O'Brien, , et al.
The British Journal of Psychiatry : the Journal of Mental Science|December 22, 2012
Cost-effectiveness analyses for mirtazapine and sertraline in dementia: randomised controlled trialRenee Romeo, Martin Knapp, Jennifer Hellier, et al.
Journal of Affective Disorders|February 8, 2026
Effectiveness of an integrated prevention programme ("JoyAge") for depressive symptoms, anxiety, and loneliness in older adults in Hong Kong: A pragmatic quasi-experimental trialTianyin Liu, Dara Kiu Yi Leung, Daniel Wong, et al.
Lancet (London, England)|October 24, 2021
Study of mirtazapine for agitated behaviours in dementia (SYMBAD): a randomised, double-blind, placebo-controlled trialSube Banerjee, Juliet High, Susan Stirling, et al.
Pageof 46